HTA Quarterly | Fall 2020
By Xcenda
HTA QUARTERLY | FALL 2020
Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea
HTA QUARTERLY | FALL 2020
Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment
HTA QUARTERLY | FALL 2020
Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China
HTA QUARTERLY | FALL 2020
Incorporating the Patient Voice in Value Assessments: The Evolution of ICER’s Approach to Patient Engagement
HTA by the Numbers
$2,340 | $3,120
The price for a typical treatment course of remdesivir for COVID-19 for people covered by government health programs in the United States (US) and other developed countries will be $2,340; the cost will be $3,120 for US patients with private insurance. The announced pricing falls below the cost-effective price range reported by the nonprofit group Institute for Clinical and Economic Review (ICER), which reported a cost-effective price range of $4,580 to $5,080. In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug, and two countries have announced doing so for around $600 per treatment course.
Heard on the street